Navigation Links
Study suggests that publicly available genome data may contain small but significant errors

Since the genome sequence of the bacterial pathogen Haemophilus influenzae was published in 1995, the genetic code of many other large, complex, medically, and commercially significant organisms including humans has also been elucidated.

However, the techniques used to derive these genetic sequences are imperfect, and many researchers may be unaware of potential errors lurking within the publicly available published, or "canonical" sequence. If an organism's genome is unstable, variable, and contains rearrangements within a population or between strains, there may be no single true linear structure that will be valid for that organism, and imposing a linear sequence may not be biologically meaningful.

Now, researchers at Cold Spring Harbor Laboratory and New York University describe a high throughput microarray technique that involves testing many samples simultaneously and which can be used to assemble physical maps and validate genomic sequence assemblies. The findings appear in the latest issue of the Journal of Computational Biology.

The research was conducted by Joseph West, John Healy, and Michael Wigler of Cold Spring Harbor Laboratory, and William Casey and Bud Mishra of NYU's Courant Institute of Mathematical Sciences. Mishra is a Professor of Computer Science and Mathematics at the Courant Institute and also has an appointment in the Department of Cell Biology at NYU's School of Medicine.

Using their micro-array hybridization method, which used flourescently labeled snippets from the genome of the fission yeast S. pombe and examined how they bind to probes arrayed on a glass slide, they were able to computationally derive the "distance" between probes in the genome and organize the probes along the genome. The resulting physical map of the S. pombe genome was compared to the corresponding map computed from publicly available S. pombe sequence. The comparison showed a small number of significant discrepancies between t heir results and that of the map derived from the public sequence released in 2002. S. pombe's genome is only about 14 million bases long (almost a thousandth of the human genome), and is widely considered to be a gold-standard in whole-genome assembly.

The authors show that with appropriate experimental conditions, array hybridization data can be used to establish a physical distance between unique arrayed probes--a sequence of DNA which in this case was 70 base pairs long. Each of the 70 base pairs is unique in the target organism's genome and serves as a landmark in that genome. These probes can then be ordered in the correct sequence in which they occur in the target genome in much the same way as a mapmaker can locate landmarks at the correct coordinates by consulting a three-dimensional rendering of a geographical map. The distance between pairs of landmarks can be used to assemble physical maps, as an aid to sequence assembly, or as an independent method for validating sequence assembly and indicating where errors need correction.

Comparing data from their inferred probe maps to the available sequence assembly, the new method provides insights into the difficulties of establishing a canonical and accurate sequence or physical map, and suggests ways that the two types of data can be combined to render increased confidence levels of the assembly.

This physical mapping technology is simple to implement and is relatively inexpensive. It is likely to have significant commercial impact through disease-related genetics studies, such as cancer and autism. In addition, it complements other mapping and sequencing technologies (e.g., Optical Mapping and Sequencing being developed by Mishra) and cancer array CGH studies (e.g., ROMA project of Wigler and a versatile cancer genome analysis project of Mishra).


'"/>

Source:New York University


Related biology news :

1. Novel Asthma Study Shows Multiple Genetic Input Required; Single-gene Solution Shot Down
2. Emory Study Tests Bone Marrow Stem Cells to Improve Circulation in Legs
3. UCLA Study Shows One-Third of Drug Ads in Medical Journals Do Not Contain References Supporting Medical Claims
4. Study Demonstrates Gene Expression Microarrays are Comparable and Reproducible
5. Study Links Ebola Outbreaks To Animal Carcasses
6. Breakthrough Microarray-based Technology for the Study of Cancer
7. NYU Study Reveals How Brains Immune System Fights Viral Encephalitis
8. Study finds more than one-third of human genome regulated by RNA
9. Leukemia Drug Breakthrough Study In New England Journal Of Medicine
10. Study identifies predictors of HIV drug resistance in patients beginning triple therapy
11. New Study from Affymetrix Laboratories Points to Changing View of How Genome Works
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/28/2016)... First quarter 2016:   , Revenues amounted ... quarter of 2015 The gross margin was 49% (27) ... the operating margin was 40% (-13) Earnings per share ... operations was SEK 249.9 M (21.2) , Outlook   ... M. The operating margin for 2016 is estimated to ...
(Date:4/15/2016)... 2016  A new partnership announced today will ... decisions in a fraction of the time it ... high-value life insurance policies to consumers without requiring ... Force Diagnostics, rapid testing (A1C, Cotinine and HIV) ... pressure, weight, pulse, BMI, and activity data) available ...
(Date:3/31/2016)... 31, 2016   ... the "Company") LegacyXChange is excited to release ... soon to be launched online site for trading 100% ... ) will also provide potential shareholders a sense of ... to an industry that is notorious for fraud. The ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... HOUSTON , June 23, 2016 ... agreement with the Cy-Fair Sports Association to serve ... of the agreement, Houston Methodist Willowbrook will provide ... education and connectivity with association coaches, volunteers, athletes ... partner with the Cy-Fair Sports Association and to ...
(Date:6/23/2016)... FRANCISCO , June 23, 2016   EpiBiome ... has secured $1 million in debt financing from Silicon ... ramp up automation and to advance its drug development ... its new facility. "SVB has been an ... beyond the services a traditional bank would provide," said ...
(Date:6/23/2016)... , June 23, 2016 Apellis Pharmaceuticals, ... 1 clinical trials of its complement C3 inhibitor, ... and multiple ascending dose studies designed to assess ... of subcutaneous injection in healthy adult volunteers. ... either as a single dose (ranging from 45 ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... exhibiting at the Pennsylvania Convention Center and will showcase its product’s latest features ... will also be presenting a scientific poster on Disrupting Clinical Trials in The ...
Breaking Biology Technology: